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Introduction {#sec005}
============

Since its development in 1996, combination antiretroviral therapy (cART) has significantly improved the quality of life of HIV-infected persons and dramatically lowered their morbidity and mortality \[[@pone.0166661.ref001]--[@pone.0166661.ref005]\]. It has become widely available in most resource-limited or developing countries since the WHO launched the "3 by 5" initiative in 2003. It was reported at the world AIDS day 2015 that 16 million people were receiving antiretroviral treatment and 7.8 million HIV-related deaths had been averted between 2000 and 2015.

In China, the National Free Antiretroviral Treatment Program (NFATP) was begun in 2002, after a pilot study \[[@pone.0166661.ref006]\]. As a public health approached ART program, NFATP has proved to have efficiently reduced mortality among HIV-infected Chinese patients \[[@pone.0166661.ref007]--[@pone.0166661.ref012]\]. The development of NFATP was in three phases. The first phase was from 2002 to 2005, the second phase,also called as the first scale-up phase, was between 2005 and 2007, and the third phase which was the further scale-up and standardization phase was from 2008 onwards \[[@pone.0166661.ref013]\]. Significant policy changes in the third phase included scale-up HIV testing among key populations and immediate initiation of ART in China. By the end of 2014, more than 363,000 patients in China had received ART \[[@pone.0166661.ref014]\]. However, concerns for the emergence of drug resistance grew during the rapid ART expansion in China. In this study, we conducted a survey of acquired HIVDR based on the WHO HIVDR surveillance protocol in order to assess the level of virological suppression and drug resistance during these years in China. Our findings would provide valuable implications for good practice of planning treatments for all people living with HIV.

Methods {#sec006}
=======

Study design and study population {#sec007}
---------------------------------

We conducted a cross-sectional survey in eight provinces or cities of China: Beijing, Jilin, Hunan, Guangxi, Sichuan, Guizhou, Yunnan and Xinjiang Province. The survey protocol was taken from the WHO recommended cross-sectional survey on acquired HIVDR in adult patients receiving ART. Patients included were 18 years or older, had begun free ART treatment in 2013, and had received first-line ART for 9--18 months at enrollment. Eligible patients were enrolled at routine clinic visits in 2014. All participants provided written informed consent.

Ethics approval {#sec008}
---------------

Institutional review board approval was granted by National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC).

Data collection {#sec009}
---------------

An interview-administered questionnaire ([S1 File](#pone.0166661.s001){ref-type="supplementary-material"}) was used for data collection. The questionnaire was administered face to face by trained local health staff in a private room. Data on demographic characteristics, ART treatment, and medicine adherence were collected during the interview.

Laboratory tests {#sec010}
----------------

Blood specimens were collected after the interview. CD4+ T cells were quantified using flow cytometry at local CDCs within 12 hours. Plasma was isolated and sent under cold chain to the laboratory at NCAIDS, China CDC where the HIV viral load was measured. Viral suppression was defined as an HIV RNA level \<1000 copies/ml. In samples with a viral load ≥1000 copies/ml, HIV drug resistance genotyping was performed at the NCAIDS laboratory by using an in-house method \[[@pone.0166661.ref015], [@pone.0166661.ref016]\]. A drug resistance mutation was identified and interpreted by using the algorithm of the Stanford HIV Drug Resistance Database (<http://hivdb.stanford.edu/pages/algs/sierra_sequence.html>). HIV drug resistance mutations were defined as those conferring low-, intermediate, or high- level resistance \[[@pone.0166661.ref017], [@pone.0166661.ref018]\].

Statistical analysis {#sec011}
--------------------

All questionnaire data were double-entered using Epidata 3.1 (The Epidata Association Odense, Denmark). Statistical Analyses ([S1 Table](#pone.0166661.s002){ref-type="supplementary-material"}) were performed using SAS V9.4 (SAS Institute Inc, Cary, North Carolina, USA). Univariate logistic regression models were constructed to explore factors associated with drug resistance. A stepwise multivariate logistic regression model was constructed to select the variables that were independently associated with drug resistance. A P value \<0.05 was considered statistically significant, and all tests were two-sided.

Results {#sec012}
=======

Demographic characteristics {#sec013}
---------------------------

This survey included 765 patients having received ART for 9--18 months ([Table 1](#pone.0166661.t001){ref-type="table"}). The mean age was 44.7 years. The majority of the subjects were male (71.4%), of Han ethnicity (79.3%), and had received Junior high school or lower education (70.7%). 42.5% were married and 35.3% were farmers. About two-thirds of the patients were infected by heterosexual transmission, followed by homosexual contact (19.2%), and intravenous drug use (8.5%). Most patients started ART with first-line regimens that included AZT+3TC+EFV/NVP (56.0%), D4T+3TC+EFV/NVP (7.6%), or TDF+3TC+EFV/NVP (29.9%). 8.2% of the patients initiated ART with PI (LPV/r)-based second-line regimens. At the time of the survey, the median duration of ART was 13.9 months (interquartile range \[IQR\] 12.6--15.0).

10.1371/journal.pone.0166661.t001

###### Characteristics of HIV patients receiving ART in China.
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  Characteristics                          Number             Percentage (%)
  ---------------------------------------- ------------------ ----------------
  Total                                    765                
  Age (mean ± SD, years)                   44.7±13.4          
  Sex                                                         
   Male                                    546                71.4
   Female                                  219                28.6
  Ethnicity                                                   
   Han                                     607                79.3
   Minorities                              158                20.7
  Education                                                   
   Illiterate                              32                 4.2
   Primary school                          189                24.7
   Junior high school                      320                41.8
   High school                             121                15.8
   Junior college or higher                103                13.5
  Married                                                     
   Yes                                     325                42.5
   No                                      440                57.5
  Occupation                                                  
   Farmer                                  270                35.3
   Other                                   495                64.7
  HIV transmission route                                      
   Heterosexual intercourse                517                67.6
   Homosexual intercourse                  147                19.2
   Drug injection                          65                 8.5
   Other                                   36                 4.7
  CD4 count before ART                                        
   0--199                                  347                45.4
   200--349                                286                37.4
   349 or above                            132                17.2
  CD4 count at survey                                         
   0--199                                  277                36.2
   200--349                                202                26.4
   349 or above                            286                37.4
  Duration of ART (months) median, IQR     13.9, 12.6--15.0   
  Missed dose in the past month                               
   Yes                                     45                 5.9
   No                                      720                94.1
  Ratio of drug intake in the past month                      
   ≥90%                                    742                97.0
   \<90%                                   23                 3.0
  Initial ART regimen                                         
   AZT/3TC/EFV or NVP                      428                56.0
   D4T/3TC/EFV or NVP                      58                 7.6
   TDF/3TC/EFV or NVP                      229                29.9
   Second-line regimens                    50                 6.5
  ART regimen at survey                                       
   AZT/3TC/EFV or NVP                      383                50.1
   D4T/3TC/EFV or NVP                      9                  1.2
   TDF/3TC/EFV or NVP                      310                40.5
   Second-line regimens                    63                 8.2
  Province or city                                            
   Beijing                                 76                 9.9
   Jilin                                   74                 9.6
   Hunan                                   96                 12.6
   Guangxi                                 256                31.5
   Sichuan                                 77                 10.1
   Guizhou                                 33                 4.3
   Yunnan                                  93                 12.2
   Xinjiang                                60                 7.8

Immunological and virological outcomes {#sec014}
--------------------------------------

Among the patients, the proportion of a CD4 count of 0--199, 200--349, and ≥350 cells/ul before ART were 45.4%, 37.4%, and 17.2%, respectively. After 13.9 months of treatment, the proportion of a CD4 count of ≥350 cells/ul was increased to 37.4%. The median CD4 count before ART increased from 222 (IQR, 215) cells/ul to 303 (IQR, 258) cells/ul at the time of the survey. The great majority of patients (700/765, 91.5%) had a plasma HIV viral load \<1000 copies/ml. Among the individuals with VLF, 64 were successful genotyped, and of these, 33 had one or more HIVDR mutations. However, the proportion of viral load failure among patients from Sichuan and Guizhou were 27% and 24%, respectively, which was higher than patients from other provinces.

HIV drug resistance and subtype {#sec015}
-------------------------------

Among the 33 patients identified with HIVDR mutations, all patients harbored HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) ([Table 2](#pone.0166661.t002){ref-type="table"}). 81.8% of these patients were also resistant to nucleoside reverse transcriptase inhibitors (NRTIs), but only 3% were resistant to both NNRTIs and PIs. The most common NNRTIs mutations were K103N (54.5%), G190A/S/R/ (27.3%), and Y181C (24.2%) in the reverse transcriptase (RT) region. NRTIs mutations were most frequently seen as M184I/V (66.7%) and K65R (39.4%) in the RT region, while PI mutations were only found to be M46L in the protease (PR) region. Among 65 patients with VLF, 56.9% (37/65) patients were subtypes of 01AE, 21.5% (14/65) were 07BC, and the rest were other subtypes. There was no corrections between the drug resistance and the subtype (P\>0.05).

10.1371/journal.pone.0166661.t002

###### HIV drug resistance mutations among HIV patients with drug resistance.
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  Antiretroviral drug                                                 N(%)        HIV drug resistance mutations, N (%)
  ------------------------------------------------------------------- ----------- --------------------------------------
  **Total**                                                           33 (100)    
  **Non-nucleoside reverse transcriptase inhibitors (NNRTIs, any)**   33 (100)    
  **Efavirenz (EFV)**                                                 33 (100)    K103N/KN,18 (54.5)
  **Nevirapine (NVP)**                                                33 (100)    G190A/S/R/GS/RS/AG,9 (27.3)
  **Etravirine (ETR)**                                                21 (63.6)   Y181C/CY,8 (24.2)
  **Rilpivirine (RPV)**                                               24 (72.7)   V179D/T/E,7 (21.2)
  K101E/N/EK,5 (15.2)                                                             
  V90I/IV,5 (15.2)                                                                
  V106M/IV,5 (15.2)                                                               
  V108I/IV,3 (9.1)                                                                
  E138A/EG/EK,3 (9.1)                                                             
  M230L,3 (9.1)                                                                   
  L100I,3 (9.1)                                                                   
  K238N/KT,2 (6.1)                                                                
  A98G/AG,2 (6.1)                                                                 
  Y188FHLY/L,2 (6.1)                                                              
  P225HP/H,2 (6.1)                                                                
  H221HY,1 (3.0)                                                                  
  F227FL,1(3.0)                                                                   
  **Nucleoside reverse transcriptase inhibitors (NRTIs, any)**        27 (81.8)   
  **Emtricitabine (FTC)**                                             25 (75.8)   M184I/V/IM,22 (66.7)
  **Lamivudine (3TC)**                                                25 (75.8)   K65R/KR,13 (39.4)
  **Abacavir (ABC)**                                                  26 (78.8)   D67N/G/DN,6 (18.2)
  **Didanosine (DDI)**                                                22 (66.7)   Y115F,5 (15.2)
  **Stavudine (D4T)**                                                 19 (57.6)   K70E/R,3 (9.1)
  **Tenofovir (TDF)**                                                 18 (54.6)   T215FIST/F,3 (9.1)
  **Azidothymidine (AZT)**                                            4 (12.1)    A62V/AV,2 (6.1)
  L74I/IL,2 (6.1)                                                                 
  V75M/IV,2 (6.1)                                                                 
  T69N,1 (3.0)                                                                    
  M41LM,1 (3.0)                                                                   
  K219E,1 (3.0)                                                                   
  **Protease inhibitors (PIs, any)**                                  1 (3.0)     
  **Tipranavir (TPV)**                                                            M46L,1 (3.0)
  **Fosamprenavir (FPV)**                                                         
  **Lopinavir (LPV)**                                                             
  **Nelfinavir (NFV)**                                                1 (3.0)     
  **Atazanavir (ATV)**                                                            
  **Darunavir (DRV)**                                                             
  **Indinavir (IDV)**                                                             
  **Saquinavir (SQV)**                                                            
  **Multi-drug resistance to NNRTI and NRTI**                         27 (81.8)   

Patient characteristics associated with HIV drug resistance {#sec016}
-----------------------------------------------------------

The risk factors for HIVDR that were significant in the univariate logistic analysis were included in the multivariate logistic regression ([Table 3](#pone.0166661.t003){ref-type="table"}). According to the univariate logistic regression model, five potential factors correlated with HIV drug resistance. In the multivariate model, the following two factors were independently correlated with HIVDR: the rate of HIVDR among patients with \<90% of drug intake in the past month were 6.0 folds higher than in patients with ≥90% of drug intake (95%CI: 1.7--20.7; P = 0.005), and Sichuan and Guizhou Provinces were 7.3 times higher than the other provinces (95%CI: 3.6--15.2; P\<0.0001).

10.1371/journal.pone.0166661.t003

###### Factors associated with HIV drug resistance among patients receiving ART in China.
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  Variable                                                Number   Drug resistance, N (%)   Crude OR(95%CI)   P-value   Adjusted OR(95%CI)   P-value
  ------------------------------------------------------- -------- ------------------------ ----------------- --------- -------------------- ----------
  Total                                                   765      33 (4.3)                                                                  
  Age (years)                                                                                                                                
   \<45                                                   416      22 (5.3)                                                                  
   ≥45                                                    349      11 (3.2)                 0.6 (0.3--1.2)    0.15                           
  Sex                                                                                                                                        
   Male                                                   546      26 (4.8)                                                                  
   Female                                                 219      7 (3.2)                  0.7 (0.3--1.5)    0.34                           
  Ethnicity                                                                                                                                  
   Han                                                    607      27 (4.4)                                                                  
   Minorities                                             158      6 (3.8)                  0.8 (0.3--2.1)    0.72                           
  Education                                                                                                                                  
   Junior high school or lower                            541      27 (5.0)                                                                  
   High school or higher                                  224      6 (2.7)                  0.5 (0.2--1.3)    0.16                           
  Married                                                                                                                                    
   Yes                                                    408      19 (4.7)                                                                  
   No                                                     357      14 (3.9)                 0.8 (0.4--1.7)    0.62                           
  Registered residence                                                                                                                       
   City                                                   421      19 (4.5)                                                                  
   Rural                                                  344      14 (4.1)                 0.9 (0.4--1.8)    0.76                           
  Occupation                                                                                                                                 
   Farmer                                                 270      10 (3.7)                                                                  
   Other                                                  495      23 (4.6)                 1.3 (0.6--2.7)    0.54                           
  Economics                                                                                                                                  
   Poor                                                   182      11 (6.0)                                                                  
   General or good                                        583      22 (3.8)                 0.6 (0.3--1.3)    0.19                           
  Medical insurance                                                                                                                          
   Yes                                                    665      32 (4.8)                                                                  
   No                                                     100      1 (1.0)                  0.2 (0.03--1.5)   0.11                           
  Social support                                                                                                                             
   No                                                     59       8 (13.8)                                                                  
   Yes                                                    706      25 (3.5)                 0.2 (0.1--0.5)    0.001                          
  Living condition                                                                                                                           
   Satisfactory                                           527      25 (4.7)                                                                  
   Not satisfactory                                       238      8 (3.4)                  0.7 (0.3--1.6)    0.39                           
  Alcohol in the past 6 months                                                                                                               
   No                                                     473      22 (4.7)                                                                  
   Yes                                                    292      11 (3.8)                 0.8 (0.4--1.7)    0.56                           
  Smoking (cigarettes/day)                                                                                                                   
   \<10                                                   613      25 (4.1)                                                                  
   ≥10                                                    152      8 (5.3)                  1.3 (0.6--3.0)    0.52                           
  Went outside for work in the past three months (days)                                                                                      
   \<30                                                   595      26 (4.4)                                                                  
   ≥30                                                    170      7 (4.1)                  0.9 (0.4--2.2)    0.89                           
  Weight                                                                                                                                     
   Increased                                              224      7 (3.1)                                                                   
   Decreased                                              71       6 (8.5)                  2.9 (0.9--8.8)    0.07                           
   No change                                              470      20 (4.3)                 1.4 (0.6--3.3)    0.47                           
  HIV transmission route                                                                                                                     
   Heterosexual intercourse                               517      25 (4.8)                                                                  
   Homosexual intercourse                                 147      3 (2.0)                  0.4 (0.1--1.4)    0.15                           
   Drug injection                                         65       3 (4.6)                  1.0 (0.3--3.2)    0.94                           
   Other                                                  36       2 (5.6)                  1.2 (0.3--5.1)    0.85                           
  Traditional Chinese Medicine treatment                                                                                                     
   Yes                                                    53       3 (5.7)                                                                   
   No                                                     712      30 (4.2)                 0.7 (0.2--2.4)    0.6                            
  Obtain medicine                                                                                                                            
   Myself                                                 739      29 (3.9)                                                                  
   Others                                                 26       4 (15.4)                 4.5 (1.4--13.8)   0.01                           
  Reminded of taking Antiretroviral drug                                                                                                     
   Telephone                                              434      14 (3.2)                                                                  
   Others                                                 331      19 (5.7)                 1.8 (0.9--3.7)    0.09                           
  Taking medicine in the workplace                                                                                                           
   Convenient                                             274      10 (3.7)                                                                  
   Inconvenient                                           136      7 (5.2)                  1.4 (0.5--3.9)    0.48                           
   Unemployed                                             355      16 (4.5)                 1.2 (0.6--2.8)    0.59                           
  Side reaction in the past month                                                                                                            
   Small side reaction                                    743      31 (4.2)                                                                  
   Big side reaction                                      22       2 (9.1)                  2.3 (0.5--10.3)   0.28                           
  Ratio of drug intake in the past month (%)                                                                                                 
   ≥90                                                    744      29 (3.9)                                                                  
   \<90                                                   21       4 (19.0)                 5.8 (1.8--18.3)   0.003     6.0(1.7--20.7)       0.005
  Ratio of on-time drug intake in the past month                                                                                             
   ≥90%                                                   748      29 (3.9)                                                                  
   \<90%                                                  17       4 (23.5)                 7.6 (2.3--24.8)   0.001                          
  Missed doses in the past month                                                                                                             
   Yes                                                    45       1 (2.2)                                                                   
   No                                                     720      32 (4.4)                 2.0 (0.3--15.3)   0.49                           
  Initial ART regimen                                                                                                                        
   Regimens without TDF                                   497      21 (4.2)                                                                  
   Regimens with TDF                                      268      12 (4.5)                 1.1 (0.5--2.2)    0.87                           
  ART regimen at survey                                                                                                                      
   Regimens without TDF                                   410      14 (3.4)                                                                  
   Regimens with TDF                                      355      19 (5.4)                 1.6 (0.8--3.2)    0.19                           
  Place of residence                                                                                                                         
   Others                                                 655      16 (2.4)                                                                  
   Sichuan and Guizhou                                    110      17 (15.5)                7.3 (3.6--14.9)   \<0.001   7.4 (3.6--15.2)      \<0.0001

Discussion {#sec017}
==========

In this study, we analyzed HIVDR data in order to evaluate the prevalence and risk factors among 765 patients who were undergoing treatment. Our findings showed that 91.5% (700/765) achieved virological suppression (VL\<1000 copies/ml) after 13.9 months of ART, which is better than the outcomes of previous surveillance studies in China \[[@pone.0166661.ref019]--[@pone.0166661.ref021]\]. 33 patients (4.3%) had verified HIVDR which is slightly lower than other countries where national free ART is available. The prevalence of HIVDR in Cameroon and Namibia were 5.3% and 5% respectively \[[@pone.0166661.ref022], [@pone.0166661.ref023]\] but significantly higher than Malawi \[[@pone.0166661.ref024]\] of 3.4%. Our results suggest that China's free ART program is providing high quality care to HIV/AIDS patients. There are several reasons to explain the low virological failure and drug resistance among HIV-infected patients receiving first-line ART. First, medical care is accessible at many levels of the health systems including provincial, prefecture, and county hospitals. Most care is provided at the community level and through outreach, with telephone calls or home visitation. Second, all doctors and health staff involved in providing ART and care management receive additional training \[[@pone.0166661.ref025]\].

Although our study showed that China has met the WHO target for 90% of patients having their viral load suppressed, as HIV/AIDS patients live longer and are on ART for life, the number of patients with drug resistance is likely to increase. A combination of strategies is required to combat drug resistance. New medicines that can more robustly cope with drug resistance mutants are needed, especially for those with common mutations such as K103N and M184I/ V \[[@pone.0166661.ref019], [@pone.0166661.ref026], [@pone.0166661.ref027]\]. M184I/V confers resistance to lamivudine, which is often the first mutation to develop in patients receiving partially suppressive triple combination therapy including lamivudine \[[@pone.0166661.ref028]\]. K103N is one of the most frequent mutations conferring resistance to most available NNRTIs \[[@pone.0166661.ref029]\].

Factors independently associated with the incidence of HIVDR were: the ratio of drug intake in the past month; and place of residence. The first factor reflected that adherence was a direct factor causing HIVDR, with 21(2.7%) patients having reported to have lower than 90% of drug intake in the past month. Similar findings had been reported in our previous studies in China \[[@pone.0166661.ref019], [@pone.0166661.ref027], [@pone.0166661.ref030]\], where poor adherence clearly leads to the occurrence of HIVDR. Good adherence can suppress plasma HIV RNA and utilize the optimum effectiveness of the ART therapy. Several studies have focused on strategies to improve adherence, including social support \[[@pone.0166661.ref031], [@pone.0166661.ref032]\], behavioral interventions \[[@pone.0166661.ref033]\], contingency management strategies \[[@pone.0166661.ref034]\], directly administered antiretroviral therapy (DAART) \[[@pone.0166661.ref035]\], and technological interventions \[[@pone.0166661.ref036]\]. The Chinese strategy focuses on education and counseling to improve the adherence of patients; but a comprehensive strategy using some of the other interventions is needed.

The reasons why patients from Sichuan and Guizhou had worse outcomes compared to patients from other provinces was unclear. We found, however, that the composition of patients from this population differed compared to patients from other provinces. Their differential risk for drug resistance may have been mediated through factors influencing adherence such as education, economic level, healthcare providers support, and adherence to ART. 78.2% of the Sichuan and Guizhou patients had received middle school education or lower compared with 69.5% in other provinces, 32.7% of patients in Sichuan and Guizhou were poor versus 22.3% s in other provinces, 59.1% of patients in Sichuan and Guizhou get support from healthcare providers compared with 89.9% in other provinces, and 14.5% in Sichuan and Guizhou had a poor adherence to ART compared with 7.8% in other provinces. There may, however, have been unmeasured confounding variables that led to this observation. Observations about drug resistance found on the population level, may not apply to individual patients. Future studies should explore health systems and individual level differences to better elucidate why resistance was greater in Sichuan and Guizhou provinces than other provinces.

We also found that regimens with or without TDF showed the same results in causing HIVDR, which needs further investigation. TDF is preferred to its predecessors AZT and d4T in the ART program because of its better safety profile \[[@pone.0166661.ref037]\] which has been recommended by WHO for HIV first-line treatment. Researchers found that patients on TDF-based first-line regimens had fewer drug-resistant mutations \[[@pone.0166661.ref038]\]. With the scale-up of TDF, evidence on this issue tends to show different results concerning mortality, the CD4 cell count, and virological failure \[[@pone.0166661.ref038]--[@pone.0166661.ref040]\]. In our study, patients at the survey on regimens with and without TDF were 5.4% (19/355) and 3.4% (14/410), respectively (P = 0.19). Further studies are needed to clarify the effects of regimens with TDF in China.

This study has some limitations. First, this was a cross-sectional study and patients who terminated treatment (due to adverse reactions, loss to follow-up, or death) would not have been sampled, which may have led to overestimated treatment effectiveness. Second, adherence was assessed by self-reporting of having missed doses in the past month, which may not reflect the true adherence. Finally, we found the drug resistance difference between Guizhou, Sichuan, and other provinces. Explaining the differences focused on the socioeconomic status of the inhabitants, but in fact transmitted drug resistance and possible presence of transmission clusters with HIV drug resistant variants may differ in different provinces which we do not know.

In conclusion, a representative national sample of HIVDR surveillance across China demonstrated excellent virological and immunological outcomes at 9--18 months among patients receiving first-line ART treatment. However, poor adherence to treatment is still a key problem regardless of the efforts on the regimens, which has led to the high rate of HIVDR. Drug resistance widely varies among provinces. More research needs to focus on the adherence of patients and long-term studies monitoring drug resistance should be completed in some select cases.
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